Psychedelic drugs have the potential to become an effective treatment for crippling mental health conditions such as depression. Here are five of the top drug developers leading their particular niches in the emerging field of psychedelic medicines.
For decades, research into the therapeutic properties of psychedelic drugs was almost snuffed out as recreational use of the substances was banned in the U.S. and Europe. In recent years, however, an emerging industry is now coalescing around the potential of hallucinogenic compounds such as lysergic acid diethylamide (LSD), psilocybin and 3,4-methylenedioxymethamphetamine (MDMA) to treat mental health conditions such as depression and post-traumatic stress disorder (PTSD). The global market is expected to grow from around $5 billion in 2020 to more than $10 billion by 2027.
While there are already a number of approved approaches to treating depression, many only last a short time, cause side effects, and cant help all patients. Psychedelic drugs are increasingly seen as a potential long-lasting alternative for patients that are left behind by existing approaches.
One of the first psychedelic drugs to be approved in the U.S. for treating a mental health indication was a nasal spray form of the drug ketamine in 2019. Branded as Spravato and marketed by Janssen, the drug was greenlit for treatment-resistant depression. However, the drug also carries risks of adverse effects including high blood pressure, sedation and the potential of drug abuse.
The hunt is now on for psychedelic compounds that are capable of treating mental health disorders long-term with fewer side effects than current treatments. With the help of experts in the field, weve drawn up a list of five of the top psychedelics developers pushing the boundaries of this exciting field.
Founded: 2018
Headquarters: Berlin, Germany
Market cap: $522 million
Atai Life Sciences was set up in response to what the founders saw as a lack of innovation in the mental health treatment landscape, along with growing opportunities surrounding the development of psychedelic medicines and digital health technology.
The firm operates with many smaller companies under its umbrella. For example, Atai fully owns the psychedelics developers EmpathBio, Revixia and Viridia. The German firm also has stakes in other players including Compass Pathways, Recognify Life Sciences and Perception Neuroscience. By working as a wide decentralized network of companies, Atai aims to streamline internal processes like HR and accounting to allow the founders to spend more time on advancing their research.
The most advanced program in Atais pipeline is a form of ketamine that may cause fewer adverse side effects than approved forms of ketamine, and is less prone to abuse by patients. Developed by the firm Perception Neuroscience, the drug is currently in a phase 2a trial to treat treatment-resistant depression.
To finance its drug development and business operations, Atai Life Sciences raised around $362 million in venture capital funding between 2020 and 2021. In June 2021, the firm took the plunge with an IPO on the Nasdaq stock market and bagged an impressive $259 million in proceeds.
Founded: 2016
Headquarters: London, U.K.
Market cap: $422 million
Compass Pathways is developing a synthetic form of psilocybin, the main psychedelic compound in magic mushrooms. Its been suggested that this hallucinogenic drug can rewire the brain to treat depression long-term after just one or two doses. In Compass Pathways lead program, the drug is given during supervised therapy sessions, where patients are provided a pill containing psilocybin, an eye mask to help them focus and a specially designed music playlist.
According to a recent phase 2b trial, Compass Pathways lead psilocybin treatment significantly reduced depressive symptoms by three weeks after a single dose. Patients given the highest dose also had benefits lasting for up to 12 weeks.
Compass Pathways is following up the trial results in a phase 3 trial planned to launch this year. The company is also testing the drug in other mental health conditions including PTSD, and supporting investigator-initiated studies in conditions including bipolar disorder, anorexia and major depressive disorder.
To fund its drug development activities, Compass Pathways raised $80 million in a Series B round in 2020, and followed up just months later with a $146.6 million IPO on the Nasdaq stock market.
Founded: 2018
Headquarters: Dublin, Ireland
Market cap: $549 million
GH Research is researching the antidepressant potential of the drug 5-methoxy-N,N-dimethyltryptamine, or 5-MeO-DMT. This molecule occurs naturally in several species of plants and even a species of toad.
In GH Researchs lead program, 5-MeO-DMT is being tested as an inhaled treatment for treatment-resistant depression. According to results from a phase 1/2 clinical trial, seven out of eight patients given the treatment went into remission seven days after receiving the treatment. The company is now planning a phase 2b trial of the drug, and later this year GH Research expects to submit applications to several European countries to run the trial.
Additionally, the company is planning a phase 2a trial for the same drug in patients with bipolar II disorder and a current depressive episode. In preclinical programs, GH Research is also developing ways to deliver 5-MeO-DMT via an injectable and intranasal approach, which could benefit certain subpopulations of patients.
GH Research jumped on the psychedelics funding trend in April 2021 when it raised a Series B round of $125 million. In June 2021, the firm went public on the Nasdaq, bagging $160 million in an IPO to fund its clinical development activities.
Founded: 1986
Headquarters: California, U.S.
The Multidisciplinary Association for Psychedelic Studies (MAPS) is a non-profit organization that has the most advanced clinical program for any psychedelic compound. MAPS is running a phase 3 program testing the benefits of the drug MDMA, also known as ecstasy, in people suffering from PTSD.
Though MDMA often makes headlines as a recreational drug, the molecule combined with intensive therapy also has the potential to regulate emotional responses that can overwhelm patients with PTSD, allowing them to cope with traumatic memories. MDMA treatment combined with therapy outperformed the placebo at treating severe PTSD in a phase 3 trial run by MAPS last year. Results from a second phase 3 trial are expected by October 2022.
MAPS is also testing the benefits of MDMA therapy in several other mental health indications including eating disorders and social anxiety in autistic adults.
An honorable mention also goes to the Canadian firm Awakn Life Sciences. With an MDMA therapy in phase 2a testing for the treatment of alcohol addiction, Awakn has one of the most advanced MDMA programs amongst the for-profit players.
Founded: 2019
Headquarters: New York, U.S. and Toronto, Canada
Market cap: $300 million
MindMed was co-founded by the entrepreneur J.R. Rahn, who suffered from mental health problems and was interested in the Silicon Valley trend of improving focus by microdosing on psychedelic drugs.
The firm is testing the benefits of the hallucinogenic drug LSD with professional supervision to treat a range of mental health conditions including generalized anxiety disorder and attention deficit hyperactivity disorder (ADHD). Like psilocybin and DMT, LSD is believed to rewire the brain and provide long-lasting mental health benefits to patients.
According to recent phase 2 results, LSD met the goal of significantly improving anxiety symptoms. MindMed is soon launching a phase 2b trial of its lead candidate in generalized anxiety disorder, and is also running a phase 2a trial of the same drug in patients with ADHD.
MindMed was one of the first psychedelics developers to go public, listing on the Canadian stock exchange NEO in 2020. MindMed then went public on the Nasdaq in April 2021. In the last three years, MindMed has raised roughly $190 million to fund its business and drug development activities.
Cover image via Anastasiia Slynko.
Thanks to feedback from MAPS, MindMed, Atai Life Sciences and Tryp Pharma
22 June 2022: Updated to correct upcoming milestones for MAPS and the pipeline of Compass Pathways.
See the rest here:
The top psychedelic drug developers leading the market - Labiotech.eu
- Review: Tripping on Utopia Complicates the History of Psychedelics - AOL - March 16th, 2024 [March 16th, 2024]
- Psychedelics Are Going Mainstream. Investing in Them Hasn't. - The Wall Street Journal - January 7th, 2024 [January 7th, 2024]
- Another Study Shows African Psychedelic Plant Ibogaine Treats Traumatic Brain Injury in Vets With 'Dramatic' Results - Good News Network - January 7th, 2024 [January 7th, 2024]
- Massachusetts Lawmakers Will Be Forced To Consider Psychedelics Legalization Measure That Activists Petitioned ... - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- VA to begin researching psychedelics as treatment option for veterans - Government Executive - January 5th, 2024 [January 5th, 2024]
- VA Is Funding New Research On Psychedelics' Benefits For Veterans With PTSD And Depression - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- VA ramps up study of psychedelic to treat PTSD - The American Legion - January 5th, 2024 [January 5th, 2024]
- Scientists predict DMT trip from cardiac activity - Big Think - January 5th, 2024 [January 5th, 2024]
- If psychedelics heal, how do they do it? | Proceedings of the National Academy of Sciences - pnas.org - January 5th, 2024 [January 5th, 2024]
- Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential | Molecular ... - Nature.com - January 5th, 2024 [January 5th, 2024]
- U.S. Rep. Correa supports using psychedelics to treat veterans with PTSD - New Santa Ana - January 5th, 2024 [January 5th, 2024]
- DEA Confirms That Psychedelic Mushroom Spores Are Federally Legal Prior To Germination - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- Psychedelics for Psych Conditions Made Their Mark in 2023 - Medpage Today - January 5th, 2024 [January 5th, 2024]
- 2023: A Good Trip Around the Sun for Psychedelics - The National Law Review - January 5th, 2024 [January 5th, 2024]
- Understanding the Role of the FDA in Advancing Psychedelic Therapy - Medriva - January 5th, 2024 [January 5th, 2024]
- MAPS PBC Closes $100m Series A, Rebrands to Lykos Therapeutics - Psychedelic Alpha - January 5th, 2024 [January 5th, 2024]
- Closing the innovation gap: Advancing psychedelic therapy and medicines in EU mental health care - Open Access Government - January 5th, 2024 [January 5th, 2024]
- The Austin Chronic: SXSW Is High on Psychedelics, as Cannabis Programming Wanes - Austin Chronicle - January 5th, 2024 [January 5th, 2024]
- This Forgotten Psychedelic Could Revolutionize Traumatic Brain Injury Treatment - Inverse - January 5th, 2024 [January 5th, 2024]
- A 'milestone' for psychedelics: Pentagon directed to study alternative treatments for veterans - Washington Times - January 5th, 2024 [January 5th, 2024]
- Psychedelic Drugs Are Rushing Towards Approval for Therapy. Here's What's Next - Singularity Hub - January 5th, 2024 [January 5th, 2024]
- The top 8 psychedelic books you need to read | GreenState - GreenState - January 5th, 2024 [January 5th, 2024]
- Lykos Therapeutics Secures $100M in Series A Funding, Rebrands from MAPS PBC - Green Market Report - January 5th, 2024 [January 5th, 2024]
- DEA Calls For Even More THC, Psilocybin And DMT To Be Produced For Research In 2024 - Marijuana Moment - January 5th, 2024 [January 5th, 2024]
- Here's What You Missed in Cannabis, Psychedelics This Week - TipRanks.com - TipRanks - January 5th, 2024 [January 5th, 2024]
- You're not tripping: State and local leaders give psychedelics another chance - Route Fifty - December 22nd, 2023 [December 22nd, 2023]
- Are Consciousness-Expanding Psychedelics Like Psilocybin More Effective Than Prozac, Zoloft, Xanax, and Other ... - Nautilus - December 22nd, 2023 [December 22nd, 2023]
- RFK, Ramaswamy And Williamson Push Psychedelics Reform On Presidential Campaign Trail - Marijuana Moment - December 22nd, 2023 [December 22nd, 2023]
- Peyote is the darling of the psychedelics renaissance. Indigenous users say it co-opts a sacred way of life - The Guardian US - December 22nd, 2023 [December 22nd, 2023]
- USask researchers explore untold history of psychedelics - News - University of Saskatchewan - USask News - December 22nd, 2023 [December 22nd, 2023]
- California Governor Says Psychedelics Have 'Profound' Healing Potential, But He's Undecided On Legalization Bill As ... - Marijuana Moment - September 25th, 2023 [September 25th, 2023]
- As psychedelic-assisted therapy grows, so does interest from a new group: chaplains - NPR - September 25th, 2023 [September 25th, 2023]
- This Maine City Moves Unanimously On Decriminalizing Psychedelics: Focus On Public Health - Benzinga - September 25th, 2023 [September 25th, 2023]
- Tech Leaders Are Finding Balance Through Microdosing Psychedelics - The Dales Report - September 25th, 2023 [September 25th, 2023]
- Chronic Pain Can Be Treated by Psychedelics, Survey Suggests - Psychedelic Spotlight - September 25th, 2023 [September 25th, 2023]
- Insights Into the First Psychedelic-Assisted Therapy Guidelines With ... - Psychedelic Spotlight - September 25th, 2023 [September 25th, 2023]
- Living with long-term cancer is depressing. Texas doctors say psychedelics could help - The Hill - July 19th, 2023 [July 19th, 2023]
- Couples Are Doing MDMA and Ketamine Therapy To Save Their Relationships - VICE - July 19th, 2023 [July 19th, 2023]
- The Way People Are Using Psychedelics Is Changing Amid Reform ... - Marijuana Moment - July 19th, 2023 [July 19th, 2023]
- [WATCH] Turn on, tune in, legalise: Could psychedelics be next in ... - MaltaToday - July 19th, 2023 [July 19th, 2023]
- Will Psychedelics Be Rescheduled After FDA Approval? - Harris Bricken - July 19th, 2023 [July 19th, 2023]
- The Psychedelic Preparedness Scale: A Tool to Optimize Trip ... - Filter - July 19th, 2023 [July 19th, 2023]
- How to Test Psychedelics for Adulterants with Testing Kits - Psychedelic Spotlight - July 19th, 2023 [July 19th, 2023]
- Cannabis Science Conference to debut in Providence, R.I., with ... - GlobeNewswire - July 19th, 2023 [July 19th, 2023]
- New Speaker Rivas weighs in on psychedelics, housing and health care worker minimum wage - Yahoo News - July 19th, 2023 [July 19th, 2023]
- TDR's Top 5 Psychedelic Developments For The Week Of July 10 - The Dales Report - July 19th, 2023 [July 19th, 2023]
- Psychedelic Treatment with Psilocybin Relieves Major Depression, Study ... - February 20th, 2023 [February 20th, 2023]
- Johns Hopkins Launches Center For Psychedelic Research - February 20th, 2023 [February 20th, 2023]
- Psilocybin Treatment for Major Depression Effective for Up to a Year ... - February 20th, 2023 [February 20th, 2023]
- Inside the Johns Hopkins Psilocybin Playlist - Hopkins Medicine - February 20th, 2023 [February 20th, 2023]
- Research Story Tip: Psychedelic Drug Psilocybin Tamps Down Brains Ego ... - February 20th, 2023 [February 20th, 2023]
- Psychedelics: Risks, benefits, and more - Medical News Today - February 18th, 2023 [February 18th, 2023]
- Psychedelic Drug Effects, Side Effects & Dangers - January 25th, 2023 [January 25th, 2023]
- Psychedelics Decriminalization Project In Berkeley, Cal Includes ... - January 6th, 2023 [January 6th, 2023]
- Ancient mummified child was drugged with psychedelics before ritual ... - December 14th, 2022 [December 14th, 2022]
- The therapeutic potential of psychedelics - Science - December 14th, 2022 [December 14th, 2022]
- Changing Lives with Psychedelics: How Connecticut researchers are using magic mushrooms to help people overcome depression, OCD - WTNH.com - November 19th, 2022 [November 19th, 2022]
- Penis Envy Mushroom | Legal Psychedelics | Magic Mushroom - November 7th, 2022 [November 7th, 2022]
- Psychedelics. Discussing natural and synthetic friends. Science, News ... - November 5th, 2022 [November 5th, 2022]
- The Harms of Psychedelics Need to Be Put Into Context - WIRED - November 5th, 2022 [November 5th, 2022]
- Packers' Aaron Rodgers says psychedelics led to his back-to-back MVP ... - October 28th, 2022 [October 28th, 2022]
- With Promise of Legalization, Psychedelic Companies Joust Over Future Profits - The New York Times - October 25th, 2022 [October 25th, 2022]
- How do psychedelics work? This brain region may explain their effects - PBS - October 21st, 2022 [October 21st, 2022]
- Why is the American right suddenly so interested in psychedelic drugs? - The Guardian - October 19th, 2022 [October 19th, 2022]
- Can Psychedelics Cure? Science Is on the Verge of Finding Out - Newsweek - October 19th, 2022 [October 19th, 2022]
- Large national survey suggests that the use of psychedelics is not associated with lifetime cancer development - PsyPost - October 19th, 2022 [October 19th, 2022]
- This Pharma Company Just Scored Another Psychedelics Patent And Set Its Sights On 70 More - Small Pharma - Benzinga - October 19th, 2022 [October 19th, 2022]
- What Made the Mushrooms Magic: Psychedelic Study Explores the Odd Evolution of Mind-Altering Fungi - The Debrief - October 19th, 2022 [October 19th, 2022]
- Psychedelics And Wellness: The Healing Company Buys PepsiCo-Backed Superfoods Company - (HLCO) - Benzinga - October 19th, 2022 [October 19th, 2022]
- What's on the Colorado ballot? Housing, psychedelics, school meals, alcohol, taxes and more | FOX31 Denver - FOX 31 Denver - October 19th, 2022 [October 19th, 2022]
- DoseConnect to Sponsor the Tech Stage at Wonderland Miami by Microdose - Benzinga - October 19th, 2022 [October 19th, 2022]
- What Is Going on With Bright Minds (DRUG) Stock Today? - InvestorPlace - October 19th, 2022 [October 19th, 2022]
- Psychedelics May Ease Fear of Death and Dying - October 17th, 2022 [October 17th, 2022]
- TDR's Top 5 Psychedelic Developments For The Week Of October 10 - The Dales Report - October 17th, 2022 [October 17th, 2022]
- DEA Wants To Boost Production Of Cannabis & Psychedelics For Research In 2023 - Benzinga - October 17th, 2022 [October 17th, 2022]
- Talk set to explore psychedelics and mental health - Reading Today - October 17th, 2022 [October 17th, 2022]
- Silo Wellness Closes Acquisition of Dyscovry Science and Its Psilocybin Pharmaceutical Biosynthesis and Research Portfolio - Yahoo Finance - October 17th, 2022 [October 17th, 2022]
- How does psilocybin rewire the brain? - Open Access Government - October 17th, 2022 [October 17th, 2022]
- HYTN Awarded Controlled Drugs and Substances Dealers License Allowing for Production and Sale of Psilocybin - Yahoo Finance - October 17th, 2022 [October 17th, 2022]
- The Healing Company acquires leading superfoods business, Your Super, and lands $150M credit facility to expand community of brands - Yahoo Finance - October 17th, 2022 [October 17th, 2022]